Rabepes20 mg

Rabepes 20 mg is a proton pump inhibitor (PPI) prescribed to reduce excess stomach acid production and treat a range of acid-related gastrointestinal disorders. It is one of the most commonly used generics for acid peptic disease management in Bangladesh due to its rapid onset of action and consistent acid suppression.

Rabeprazole is indicated for the treatment of the following conditions:

• Active duodenal ulcer – promotes healing of ulcers in the first part of the small intestine.
• Active benign gastric ulcer – treats non-cancerous ulcers of the stomach lining.
• Erosive or ulcerative gastro-esophageal reflux disease (GERD) – heals inflammation and erosion of the esophagus caused by acid reflux.
• Long-term maintenance therapy for GERD – prevents relapse of symptoms and esophageal healing after initial treatment.
• Symptomatic GERD – relieves heartburn and regurgitation in moderate to very severe reflux disease, even without visible esophageal damage.
• Zollinger-Ellison syndrome – controls excessive gastric acid secretion caused by gastrin-secreting tumors.
• Helicobacter pylori (H. pylori) eradication – used in combination with antibiotics as part of triple therapy to treat peptic ulcer disease caused by H. pylori infection.

Rabeprazole is also frequently prescribed off-label for stress ulcer prophylaxis, NSAID-associated gastric protection, and functional dyspepsia, based on clinical judgment.

Proton Pump Inhibitor (PPI)

Rabeprazole belongs to the class of substituted benzimidazole proton pump inhibitors (PPIs). It works by irreversibly binding to and inhibiting the hydrogen-potassium ATPase enzyme (H+/K+-ATPase), commonly known as the "proton pump," located on the secretory surface of gastric parietal cells.

Since this enzyme carries out the final step of acid production in the stomach, its inhibition results in a marked and long-lasting suppression of both basal and stimulated gastric acid secretion, regardless of the triggering stimulus (histamine, acetylcholine, or gastrin).

Key pharmacological characteristics include:

• Rabeprazole is a prodrug that becomes activated in the acidic environment of the parietal cell canaliculi, where it converts to its active sulfenamide form.
• It provides rapid and potent acid suppression, with a significant reduction in gastric acidity typically observed within one hour of the first dose.
• Acid secretion returns to normal within 2–3 days after stopping treatment, as new proton pumps are synthesized.
• Unlike some other PPIs, Rabeprazole's activation is less dependent on specific liver enzyme (CYP2C19) genotypes, resulting in more predictable acid suppression across different patients.

Although neither the time of day nor food intake was demonstrated to have any effect on Rabepes 20 mg activity, taking these pills in the morning before eating will make it easier for patients to adhere to the treatment plan. Patients should be informed that the pills of rabeprazole should not be chewed or mashed but rather consumed whole.

Rabepes 20 mg causes a profound and long-lasting reduction in gastric acid secretion, which can alter the absorption of drugs whose bioavailability depends on stomach pH. The following interactions are clinically important:

Always inform your doctor or pharmacist about all medications, herbal products, and supplements you are taking before starting Rabepes 20 mg.

Rabepes 20 mg is generally well-tolerated in both short-term and long-term use. Most side effects are mild and resolve on their own or after stopping the medication.

Common Side Effects

• Headache
• Diarrhoea
• Abdominal pain
• Nausea and vomiting
• Constipation
• Dry mouth
• Increased or decreased appetite
• Muscle pain (myalgia)
• Drowsiness and dizziness

Less Common but Serious Side Effects

• Blood disorders such as thrombocytopenia (low platelets) and neutropenia (low white blood cells)
• Liver enzyme abnormalities or hepatic dysfunction
• Severe hypomagnesaemia (low magnesium), which may cause fatigue, muscle cramps, tremors, or irregular heartbeat with long-term use
• Increased risk of bone fractures (hip, wrist, spine) with high-dose, long-term therapy
• Vitamin B12 deficiency with prolonged use
• Subacute cutaneous lupus erythematosus (SCLE) — a rare skin reaction, more likely to appear on sun-exposed skin
• Increased susceptibility to gastrointestinal infections such as Salmonella, Campylobacter, and Clostridium difficile

Patients experiencing severe rash, joint pain, persistent diarrhoea, signs of kidney problems (swelling, reduced urination), or unusual bleeding should seek medical attention immediately.

Pregnancy: Rabeprazole is classified under US FDA Pregnancy Category C. Animal reproduction studies have not shown evidence of impaired fertility or fetal harm; however, there are no adequate, well-controlled studies confirming safety in pregnant women. Rabeprazole is contraindicated during pregnancy and should only be used if a physician determines the potential benefit clearly outweighs the risk.

Lactation: Rabeprazole is likely excreted in human breast milk. Since the effects on a nursing infant are not well established, a decision must be made either to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the drug for the mother's health. It is contraindicated during breastfeeding unless specifically advised by a doctor.

• Symptomatic relief with Rabeprazole does not rule out gastric or esophageal malignancy. Malignancy should be excluded before starting treatment, especially in patients with alarm symptoms (unexplained weight loss, difficulty swallowing, persistent vomiting, or GI bleeding).
• Patients on long-term therapy, particularly beyond one year, should undergo regular medical surveillance.
• Long-term or high-dose use may modestly increase the risk of hip, wrist, and spine fractures, especially in elderly patients or those with existing risk factors for osteoporosis. Adequate calcium and vitamin D intake is recommended for at-risk patients.
• Tablets must be swallowed whole and should never be chewed or crushed, due to the gastro-resistant coating.
• Monitor magnesium levels in patients on prolonged PPI therapy, especially those also taking digoxin or diuretics, due to the risk of hypomagnesaemia.
• Long-term use may reduce vitamin B12 absorption; monitor patients with pre-existing low B12 stores or relevant risk factors.
• Discontinue use and consult a doctor promptly if skin lesions consistent with subacute cutaneous lupus erythematosus (SCLE) develop, particularly in sun-exposed areas.
• Increased risk of intestinal infections (e.g., Salmonella, Campylobacter, C. difficile) has been associated with long-term acid suppression.
• For patients undergoing testing for neuroendocrine tumors (Chromogranin A levels), Rabeprazole should be stopped for at least 5 days prior to testing, as it can falsely elevate CgA levels.
• Use with caution in patients with severe hepatic impairment, as clinical data in this population is limited.

Clinical experience with Rabeprazole overdose is limited. The highest documented exposures have not exceeded 60 mg twice daily or 160 mg once daily, and effects in these cases were generally minimal, consistent with the known side-effect profile, and reversible without medical intervention.

There is no specific antidote for Rabeprazole overdose. Because the drug is extensively protein-bound, it is not effectively removed by dialysis. Management of overdose should be symptomatic and supportive.

If an overdose is suspected, contact a doctor or the nearest poison control center immediately. Symptoms that may indicate overdose include excessive drowsiness, confusion, blurred vision, and rapid heartbeat.

• Store below 30°C, in a cool and dry place.
• Protect from light and moisture.
• Keep the tablets in their original blister pack until ready for use.
• Keep out of reach of children.

• Renal impairment: No dosage adjustment is required for patients with renal impairment.
• Hepatic impairment: No dose adjustment is needed for mild to moderate hepatic impairment. Caution is advised when initiating treatment in patients with severe hepatic dysfunction, as clinical data is limited.
• Elderly patients: No specific dose adjustment is required, though elderly patients on long-term therapy should be monitored for increased fracture risk and hypomagnesaemia.
• Pediatric use: Rabeprazole is approved for GERD treatment in children aged 1–11 years at weight-based doses. It is generally not recommended for other indications in children due to insufficient safety and efficacy data.
• Pregnant and breastfeeding women: Contraindicated; see the Pregnancy & Lactation section for details.

Proton Pump Inhibitor

The gastric H+/K+-ATPase at the secretory surface of the stomach parietal cell is inhibited by rabeprazole, which reduces gastric acid secretion. It has been said that Rabeprazole acts as an inhibitor of the gastric proton pump since this enzyme is thought to be the acid (proton) pump within the parietal cell.

FDA pregnancy category "C" in the US. There is no proof that Rabeprazole affects fertility or causes harm to the fetus, according to studies done on animals. Nevertheless, there isn't any good, controlled research on pregnant women. Since that rabeprazole is probably excreted in human milk, a choice should be made regarding whether to stop breastfeeding or to stop the medication, taking into account the significance of the medication to the mother.

Hepatic and renal impairment: Patients who have these conditions don't require dosage adjustments. Rabeprazole is not advised for usage in pediatric populations since there are insufficient data on its safety and effectiveness.